Tirzepatide stock: what it means for your treatment and what to do next

Tirzepatide stock issues in the UK stem from manufacturer allocation limits, not poor-quality supply, genuine pens come through the licensed UK distribution chain only.
Dose-specific shortages are common: a particular strength may be unavailable while others remain in stock, which can affect titration plans.
A GPhC-registered pharmacy is the only legal route to a genuine supply, any seller offering tirzepatide without requiring a prescription is a serious red flag.
Your prescriber should be the first call when a dose is out of stock, they can advise on holding, bridging, or adjusting, and document any interruption to your treatment.

Tirzepatide stock in the UK has been variable since the medicine's launch, and the decision you face — wait it out, find a regulated private supplier, or consider switching — depends on a few clear factors. Tirzepatide (Mounjaro) is a prescription-only medicine; supply is managed through the licensed UK pharmaceutical chain, and demand has consistently outpaced expectations since NICE recommended it in December 2024. If you're trying to work out your next step, this page explains what drives the shortages, what to check, and how to keep your treatment on track safely.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How to navigate a tirzepatide stock gap without putting your health at risk

Why tirzepatide stock runs short at specific doses

The shortage pattern that most people encounter isn't a single, blanket gap, it's dose-specific. Eli Lilly allocates UK supply through a licensed wholesaler network, and demand at each strength doesn't move evenly. The 5mg and 7.5mg pens, which are the most commonly prescribed titration steps, have seen the tightest constraints at various points since launch. The 2.5mg starter dose has generally been more available because patients spend only one month at that level before moving on.

Understanding this matters because your next clinical decision isn't identical whether you're on your first pen or your eighth. If your usual dose is temporarily unavailable, the options (holding at your current dose an extra week, sourcing the same strength from a different GPhC-registered pharmacy, or temporarily stepping down with prescriber guidance) each carry different clinical implications. A question our prescribers hear most weeks is whether it's safe to skip ahead to a higher dose when the prescribed strength is out of stock. The short answer is no: dose increases need clinical sign-off precisely because your tolerance hasn't been confirmed at an untried level. The Mounjaro treatment page sets out how the titration schedule works and why each step matters.

NICE's recommendation covering tirzepatide (TA1026, published December 2024) has significantly expanded the eligible population in the UK, which has placed further pressure on supply that manufacturers are still working to meet. The NICE appraisal of tirzepatide is worth reading if you want to understand the clinical evidence that drove that recommendation.

The stock decision you actually have to make

When a dose is out of stock at your current provider, the realistic options split into three branches. First, wait: if the shortage is short-term and your prescriber confirms it's clinically appropriate to hold your current dose an extra week or two, this is often the lowest-risk path. Most pharmacies can give a realistic restock estimate, and a brief pause rarely derails progress made over months.

Second, find a GPhC-registered alternative. Not every pharmacy sources from the same wholesale allocation. A regulated private pharmacy with its own stock pipeline may have a dose your usual supplier doesn't. The GPhC pharmacy register lets you verify any UK pharmacy before you hand over a prescription or payment. This is the verification step that separates a legitimate option from a risk.

Third, if your current provider can't give a timeline and switching prescribers feels disruptive, a same-day clinical review at a different service can get you a new prescription for the dose you need, assuming you can evidence your current treatment and dose. At nume, transfer patients provide documentation of their current treatment before any dose is confirmed, so the prescriber is working from the same clinical picture your previous clinician had. You can read about how that process works on the how to get tirzepatide page.

Cost context is part of this decision too. If you're considering switching services because of supply, it's worth understanding what different providers include in their quoted price. Some charge separately for the consultation, the prescription, and delivery. The Mounjaro cost page breaks down what to look for.

The one option that isn't on the table: unverified online sellers

When pens are hard to find, sellers without a pharmacy licence fill the gap online. This is where the risk concentrates sharply. The MHRA has warned publicly and repeatedly about fake tirzepatide pens entering the UK market, counterfeit products seized in large quantities, including pens found to contain insulin rather than tirzepatide, which has caused hospitalisations. Reporting a suspect seller is straightforward via the MHRA's Yellow Card scheme, which handles reports about both side effects and illicit medicine sellers.

The markers of an unverified seller are consistent: no requirement for a clinical consultation, no GPhC registration number you can check, prices far below the typical UK market range, and often a social-media or messaging-app contact route rather than a regulated website. A stock shortage creates urgency, and urgency is exactly the condition these sellers exploit. A genuine UK pharmacy can't guarantee you'll never face a wait, but it can guarantee the medicine is what it says it is.

If you're at the point of looking for a regulated private route and want clinical review without a waiting list, the treatment options page explains what a consultation with our prescribers involves and what we'd need from you.

Keeping your treatment on track through a supply gap

A short interruption to tirzepatide, handled with prescriber guidance, doesn't have to mean losing ground. The key is not improvising. If you miss doses during a stock gap, your prescriber needs to know, both to document the interruption and to advise on restarting. In some cases, restarting after a gap of more than a few weeks may mean dropping back a dose level to rebuild tolerance, and if you need to buy tirzepatide 10mg or are considering whether to buy tirzepatide 15mg after a pause, that's a clinical call, not a self-management decision.

Lifestyle factors that supported your weight loss don't switch off because the pen isn't available. Keeping to the dietary pattern you established on treatment, staying hydrated, and maintaining whatever activity level you've built up all matter during a gap. They also matter when you restart, the medicine works alongside changed habits, not instead of them. The weight loss overview has more on the evidence for combined approaches.

If you're mid-titration and concerned about what a pause means for your specific situation, speaking to a prescriber is always the right move. Our clinical team can be reached through the contact page, and the FAQs cover some of the most common questions about treatment interruptions. If you want a same-day clinical review of your options and would like to tirzepatide buy online through a regulated service, check your eligibility and speak to our prescribers through the free consultation.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions